Illumina welcomes Anna Richo to its Board of Directors

– USA, CA –  Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Anna Richo to its Board of Directors effective May 16, 2024, bringing more than 30 years of regulated-industry experience as an attorney and legal executive, with extensive experience in compliance and business ethics, intellectual property, and corporate litigation.

“I am thrilled to welcome Anna to our Board of Directors. n today’s evolving business and regulatory environment, her extensive global legal, compliance, and regulatory experience, including at biotechnology, biopharmaceutical, and medtech companies, will enhance our evaluation and understanding of the risks and opportunities associated with Illumina’s expanding worldwide operations,” said CEO Jacob Thaysen.

About Anna Richo

Anna Richo serves as Corporate SVP, Strategic Advisor to the General Counsel, and CEO at Cargill, Inc. a global food production and agricultural company.

Anna Richo formerly served as Corporate SVP, General Counsel, CCO, and Corporate Secretary at Cargill, where she oversaw the company’s corporate governance, global ethics and compliance, global security, global government relations, law, and shareholder relations functions.

Before joining Cargill, Anna Richo was EVP and General Counsel at UCB, a biopharmaceutical company based in Belgium. She also served as SVP and CCO at Amgen, a global biotechnology company, and as Chief Litigation Counsel, Associate General Counsel, and VP of Law at Baxter Healthcare.

Anna Richo also serves as a member of Exelon’s Board of Directors, as a member of the Cargill Foundation Board of Directors, the Board of Trustees for DePaul University, and the Children’s Minnesota Governance Board.

Anna Richo holds a B.S. in Industrial and Labor Relations from Cornell University and a J.D. from DePaul University College of Law.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.